Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Archer

Showing results (571-580 of 594) with videos related to

Pageof 60
Sort By:
Cancer Research|October 5, 2001
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B studyS P Whitman, K J Archer, L Feng, et al.
Leukemia|February 20, 2003
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cellsM I Klisovic, E A Maghraby, M R Parthun, et al.
Laboratory Animals|April 8, 2006
Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animalsP J O'Brien, D E C Smith, T J Knechtel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
American Journal of Ophthalmology|August 12, 2018
Enhanced Tomographic Assessment to Detect Corneal Ectasia Based on Artificial IntelligenceBernardo T Lopes, Isaac C Ramos, Marcella Q Salomão, et al.
Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B StudyK Mrózek, T W Prior, C Edwards, et al.
Veterinary Pathology|April 22, 2008
Histopathologic, immunohistochemical, and cytologic analysis of feline myeloma-related disorders: further evidence for primary extramedullary development in the catP J Mellor, S Haugland, K C Smith, et al.
Haematologica|August 16, 2019
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemiaMarius Bill, Deedra Nicolet, Jessica Kohlschmidt, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemiaKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
Pageof 60

Showing results (571-580 of 594) with videos related to

Sort By:
Pageof 60
Cancer Research|October 5, 2001
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B studyS P Whitman, K J Archer, L Feng, et al.
Leukemia|February 20, 2003
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cellsM I Klisovic, E A Maghraby, M R Parthun, et al.
Laboratory Animals|April 8, 2006
Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animalsP J O'Brien, D E C Smith, T J Knechtel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
American Journal of Ophthalmology|August 12, 2018
Enhanced Tomographic Assessment to Detect Corneal Ectasia Based on Artificial IntelligenceBernardo T Lopes, Isaac C Ramos, Marcella Q Salomão, et al.
Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B StudyK Mrózek, T W Prior, C Edwards, et al.
Veterinary Pathology|April 22, 2008
Histopathologic, immunohistochemical, and cytologic analysis of feline myeloma-related disorders: further evidence for primary extramedullary development in the catP J Mellor, S Haugland, K C Smith, et al.
Haematologica|August 16, 2019
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemiaMarius Bill, Deedra Nicolet, Jessica Kohlschmidt, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemiaKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
Pageof 60